Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: Phase Il results

Anti-Cancer Drugs

Volumn 20, Issue 3, 2009, Pages 204-207

  Michalaki, Vasiliki ^a   Gennatas, Spyridon ^a   Gennatas, Konstantine ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Capecitabine; Chemotherapy; Docetaxel; Metastatic breast cancer

Indexed keywords

CAPECITABINE; DOCETAXEL; ESTROGEN RECEPTOR; FLUCONAZOLE; LOPERAMIDE; PROGESTERONE RECEPTOR; PYRIDOXINE;

ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; LOW DRUG DOSE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA; CYCLOPHOSPHAMIDE; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; METHOTREXATE; MIDDLE AGED; NEUTROPENIA; PACLITAXEL; PERIPHERAL NERVOUS SYSTEM DISEASES; TAXOIDS; TREATMENT OUTCOME;

EID: 61749098797     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328327d492     Document Type: Article

References (18)

1. Nabholtz JM, Falkson G, Campos D, Szanto J, Martin M, Chan S, et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 2003; 21:968-975.
2. Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, Rowinsky EK, Wood WC. Phase III trial of doxorubicin, paclitaxel and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 2003; 21:588-592.
3. Chan S, Friedrichs K, Noel D, Pintér T, Van Belle S, Vorobiof D, et al. Prospective randomised trial of docetaxel versus doxorubicin in patients with metastatic breast cancer: the 303 Study Group. J Clin Oncol 1999; 17:2341-2354.
4. O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002; 20:2812-2823.
5. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357:2666-2676.
6. Miles D, Chan A, Romieu G, Dirix LY, Cortes J, Pivot X, et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. J Clin Oncol 2008; 26 (Suppl 18):1088s (LBA1011).
7. Toi M, Bando H, Horiguchi S, Takada M, Kataoka A, Ueno T, et al. Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer. Br J Cancer 2004; 90:2338-2343.
8. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 1998; 4:1013-1019.
9. Puglisi F, Andreetta C, Valent F, Minisini AM, Rijavec E, Russo S, et al. Anthracyclines and taxanes induce the upregulation of thymidine phosphorylase in breast cancer cells. Anticancer Drugs 2007; 18:883-888.
10. Leonard R, O'Shaughnessy J, Vukelja S, Gorbounova V, Chan-Navarro CA, Maraninchi D, et al. Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage? Ann Oncol 2006; 17:1379-1385.
11. Beslija S, Obralic N, Basic H, Tatarevic A, Naila M, Banjin M, et al. Randomized trial of sequence vs. combination of capecitabine (X) and docetaxel CT): XT vs. T followed by X after progression as first-line therapy for patients (pts) with metastatic breast cancer (MBC). J Clin Oncol 2006; 24 (Suppl 18):571.
12. Chan S, Romieu G, Huober J, Tubiana-Hulin M, Schneeweiss A, Lluch A, et al. Phase III study of gemcitabine plus docetaxel versus capecitabine plus docetaxel for anthracycline-pretreated metastatic breast cancer patients: survival results [abstract 1078]. Breast Cancer Res Treat 2007; 106 (Suppl 1):S68.
13. Soto C, Torrecillas L, Reyes S, Ramirez M, Perez L, Cervantes G, et al. Capecitabine (X) and taxanes in patients (pts) with anthracycline- pretreated metastatic breast cancer (MBC): sequential vs. combined therapy results from a MOSG randomized phase III trial. J Clin Oncol 2006; 24 (Suppl 18):570.
14. Mavroudis D, Papakotoulas P, Ardavanis A, Kakolyris S, Kouroussis CH, Malamos N, et al. Docetaxel plus epirubicin versus docetaxel plus capecitabine as first line treatment in patients with advanced breast cancer. Final results of a multicenter phase III trial (abstract 136O). Ann Oncol 2008; 19 (Suppl 8):viii63.
15. Blum JL, Dees EC, Chacko A, Doane L, Ethirajan S, Hopkins J, et al. Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 2006; 24:4384-4390.
16. Gradishar WJ, Meza LA, Amin B, Samid D, Hill T, Chen YM, et al. Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II study. J Clin Oncol 2004; 22:2321-2327.
17. Puglisi F, Cardellino GG, Crivellari D, Di Loreto C, Magri MD, Minisini AM, et al. Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer. Ann Oncol 2008; 19:1541-1546.
18. Mrozek E, Ramaswamy B, Young D, Rhoades CA, Kendra K, Allen J, et al. Phase Il study of weekly docetaxel and capecitabine in patients with metastatic breast cancer. Clin Breast Cancer 2006; 7:141-145.